Carter Keller

Carter Keller has a diverse work experience in the biotechnology and pharmaceutical industries. Carter is currently the Chief Executive Officer of GigaGen Inc, where they have been since October 2021. Prior to this role, they served as the Chief Operating Officer of GigaGen Inc from December 2014 to October 2021, leading various aspects of the company including operations, business development, marketing, finance, and strategy. During their tenure, they successfully closed a $50 million Series A financing and raised more than $62 million in grants, equity, and partnership revenue.

In addition to their role at GigaGen Inc, Carter Keller is a Co-Founder of GigaMune, a company focused on advancing T cell therapies for cancer. Carter played a key role in developing the company's industry-leading technology for capturing and engineering T cell receptors (TCRs) directed against solid tumor targets.

Before joining GigaGen and GigaMune, Carter Keller worked at Exelixis as a Senior Director of Marketing from August 2012 to September 2014. In this role, they were responsible for launch planning and sales strategy for oncology programs, including the successful launch of Cometriq into medullary thyroid cancer in the US and EU. Carter also managed all ex-US marketing and sales management for Cometriq and planned launch strategies for Cabometx in RCC and prostate cancer.

Prior to Exelixis, Carter Keller held the position of Director of Strategic Marketing at Achaogen from December 2010 to July 2012. In this role, they were responsible for managing various aspects of communication, marketing, KOL relationships, market research, analysis/forecasting, drug development, competitive intelligence, and business development for a development-stage pharmaceutical company. Carter played a pivotal role in creating frameworks to assess corporate strategy and provided commercial assessments, market analysis, and marketing collateral for Achaogen's pipeline.

Carter Keller began their career at Genentech in 2004, initially working as a Market Planning Manager from July 2004 to July 2006. Carter then held various roles within the company, including Senior Market Planning Manager, Principal, and Group Manager of New Product Planning and Commercial Assessments. In these positions, they led teams responsible for developing and implementing commercial strategies for Genentech's oncology pipeline. Carter also provided commercial rationale and valuations for BD opportunities, led cross-portfolio initiatives, and supported negotiations during the Roche acquisition.

Before Genentech, Carter Keller gained experience at Burrill & Company as an Associate Intern and at Ingenio as a Business Development Manager. Carter started their career as a Junior Associate at APM.

Throughout their career, Carter Keller has demonstrated expertise in strategic planning, business development, marketing, and commercial assessments in the biotechnology and pharmaceutical sectors.

Carter Keller's education history begins with their high school diploma, which they obtained from Phillips Academy Andover in 1993. Following that, they attended Stanford University from 1993 to 1997, where they pursued a degree in Chemical Engineering and Premed. Later on, from 2002 to 2004, Carter pursued an MBA from the University of California, Berkeley, Haas School of Business, specializing in Investments, Entrepreneurship, and Biotechnology.